Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
Bibby, Michael C. Hill, B.T. Holwell, S.E.
Bibby, Michael C.
Hill, B.T.
Holwell, S.E.
Publication Date
2001
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Anti-vascular effects of the novel Vinca alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation Vinca. Administration of the maximum tolerated dose of either vinflunine (50 mg kg-1) or vinorelbine (8 mg kg-1) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours.
Version
No full-text in the repository
Citation
Bibby MC, Hill BT and Holwell SE (2001) Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. British Journal of Cancer. 84(2): 290-295.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article